Ruxolitinib

TERMINATED · PHASE2 · Myelofibrosis

Sponsor decision

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.